Future paradigms for precision oncology

J 2016

Future paradigms for precision oncology

KLEMENT, Giannoula Lakka; Knarik ARKUN; Dalibor VALÍK; Tina ROFFIDAL; Ali HASHEMI et. al.

Základní údaje

Originální název

Future paradigms for precision oncology

Autoři

Vydání

Oncotarget, Albany, Impact Journals, 2016, 1949-2553

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30200 3.2 Clinical medicine

Stát vydavatele

Spojené státy

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 5.168

Kód RIV

RIV/00216224:14110/16:00088934

Organizační jednotka

Lékařská fakulta

DOI

https://doi.org/10.18632/oncotarget.9488

UT WoS

000385402300150

EID Scopus

2-s2.0-84979620592

Klíčová slova anglicky

precision medicine; targeted therapy; genomics; metronomic chemotherapy

Štítky

EL OK

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 26. 4. 2021 13:27, Mgr. Tereza Miškechová

Anotace

V originále

Research has exposed cancer to be a heterogeneous disease with a high degree of inter-tumoral and intra-tumoral variability. Individual tumors have unique profiles, and these molecular signatures make the use of traditional histology-based treatments problematic. The conventional diagnostic categories, while necessary for care, thwart the use of molecular information for treatment as molecular characteristics cross tissue types. This is compounded by the struggle to keep abreast the scientific advances made in all fields of science, and by the enormous challenge to organize, cross-reference, and apply molecular data for patient benefit. In order to supplement the site-specific, histology-driven diagnosis with genomic, proteomic and metabolomics information, a paradigm shift in diagnosis and treatment of patients is required. While most physicians are open and keen to use the emerging data for therapy, even those versed in molecular therapeutics are overwhelmed with the amount of available data. It is not surprising that even though The Human Genome Project was completed thirteen years ago, our patients have not benefited from the information. Physicians cannot, and should not be asked to process the gigabytes of genomic and proteomic information on their own in order to provide patients with safe therapies. The following consensus summary identifies the needed for practice changes, proposes potential solutions to the present crisis of informational overload, suggests ways of providing physicians with the tools necessary for interpreting patient specific molecular profiles, and facilitates the implementation of quantitative precision medicine. It also provides two case studies where this approach has been used.

Návaznosti

LM2015090, projekt VaV

Název: Český národní uzel Evropské sítě infrastruktur klinického výzkumu (Akronym: CZECRIN)

Investor: Ministerstvo školství, mládeže a tělovýchovy ČR, CZECRIN - Český národní uzel Evropské sítě infrastruktur klinického výzkumu

LQ1601, projekt VaV

Název: CEITEC 2020 (Akronym: CEITEC2020)

Investor: Ministerstvo školství, mládeže a tělovýchovy ČR, CEITEC 2020

NV16-33209A, projekt VaV

Název: Sekvenování nové generace a expresní profilování jako diagnostický podklad pro návrhy individualizovaných léčebných plánů pro děti se solidními nádory

NV16-34083A, projekt VaV

Název: Receptorové tyrozinkinázy a navazující signální dráhy jako potenciální cíle léčby refrakterních solidních nádorů dětského věku

90089, velká výzkumná infrastruktura

Název: BBMRI-CZ II

Citovat

KLEMENT, Giannoula Lakka; Knarik ARKUN; Dalibor VALÍK; Tina ROFFIDAL; Ali HASHEMI; Christos KLEMENT; Paolo CARMASSI; Edward RIETMAN; Ondřej SLABÝ; Pavel MAZÁNEK; Peter MÚDRY; Gabor KOVACS; Csongor KISS; Koen NORGA; Dobrin KONSTANTINOV; Nicolas ANDRÉ; Irene SLAVC; Henk van DEN BERG; Alexandra KOLENOVA; Leoš KŘEN; Jiří TŮMA; Jarmila SKOTÁKOVÁ a Jaroslav ŠTĚRBA. Future paradigms for precision oncology. Oncotarget. Albany: Impact Journals, 2016, roč. 7, č. 29, s. 46813-46831. ISSN 1949-2553. Dostupné z: https://doi.org/10.18632/oncotarget.9488.

@article{1366314,
   author = {Klement, Giannoula Lakka and Arkun, Knarik and Valík, Dalibor and Roffidal, Tina and Hashemi, Ali and Klement, Christos and Carmassi, Paolo and Rietman, Edward and Slabý, Ondřej and Mazánek, Pavel and Múdry, Peter and Kovacs, Gabor and Kiss, Csongor and Norga, Koen and Konstantinov, Dobrin and André, Nicolas and Slavc, Irene and Den Berg, Henk van and Kolenova, Alexandra and Křen, Leoš and Tůma, Jiří and Skotáková, Jarmila and Štěrba, Jaroslav},
   article_location = {Albany},
   article_number = {29},
   doi = {https://doi.org/10.18632/oncotarget.9488},
   keywords = {precision medicine; targeted therapy; genomics; metronomic chemotherapy},
   language = {eng},
   issn = {1949-2553},
   journal = {Oncotarget},
   title = {Future paradigms for precision oncology},
   url = {http://dx.doi.org/10.18632/oncotarget.9488},
   volume = {7},
   year = {2016}
}

TY  - JOUR
ID  - 1366314
AU  - Klement, Giannoula Lakka - Arkun, Knarik - Valík, Dalibor - Roffidal, Tina - Hashemi, Ali - Klement, Christos - Carmassi, Paolo - Rietman, Edward - Slabý, Ondřej - Mazánek, Pavel - Múdry, Peter - Kovacs, Gabor - Kiss, Csongor - Norga, Koen - Konstantinov, Dobrin - André, Nicolas - Slavc, Irene - Den Berg, Henk van - Kolenova, Alexandra - Křen, Leoš - Tůma, Jiří - Skotáková, Jarmila - Štěrba, Jaroslav
PY  - 2016
TI  - Future paradigms for precision oncology
JF  - Oncotarget
VL  - 7
IS  - 29
SP  - 46813-46831
EP  - 46813-46831
PB  - Impact Journals
SN  - 19492553
KW  - precision medicine
KW  - targeted therapy
KW  - genomics
KW  - metronomic chemotherapy
UR  - http://dx.doi.org/10.18632/oncotarget.9488
L2  - http://dx.doi.org/10.18632/oncotarget.9488
N2  - Research has exposed cancer to be a heterogeneous disease with a high degree of inter-tumoral and intra-tumoral variability. Individual tumors have unique profiles, and these molecular signatures make the use of traditional histology-based treatments problematic. The conventional diagnostic categories, while necessary for care, thwart the use of molecular information for treatment as molecular characteristics cross tissue types. This is compounded by the struggle to keep abreast the scientific advances made in all fields of science, and by the enormous challenge to organize, cross-reference, and apply molecular data for patient benefit. In order to supplement the site-specific, histology-driven diagnosis with genomic, proteomic and metabolomics information, a paradigm shift in diagnosis and treatment of patients is required. While most physicians are open and keen to use the emerging data for therapy, even those versed in molecular therapeutics are overwhelmed with the amount of available data. It is not surprising that even though The Human Genome Project was completed thirteen years ago, our patients have not benefited from the information. Physicians cannot, and should not be asked to process the gigabytes of genomic and proteomic information on their own in order to provide patients with safe therapies. The following consensus summary identifies the needed for practice changes, proposes potential solutions to the present crisis of informational overload, suggests ways of providing physicians with the tools necessary for interpreting patient specific molecular profiles, and facilitates the implementation of quantitative precision medicine. It also provides two case studies where this approach has been used.
ER  -

KLEMENT, Giannoula Lakka; Knarik ARKUN; Dalibor VALÍK; Tina ROFFIDAL; Ali HASHEMI; Christos KLEMENT; Paolo CARMASSI; Edward RIETMAN; Ondřej SLABÝ; Pavel MAZÁNEK; Peter MÚDRY; Gabor KOVACS; Csongor KISS; Koen NORGA; Dobrin KONSTANTINOV; Nicolas ANDRÉ; Irene SLAVC; Henk van DEN BERG; Alexandra KOLENOVA; Leoš KŘEN; Jiří TŮMA; Jarmila SKOTÁKOVÁ a Jaroslav ŠTĚRBA. Future paradigms for precision oncology. \textit{Oncotarget}. Albany: Impact Journals, 2016, roč.~7, č.~29, s.~46813-46831. ISSN~1949-2553. Dostupné z: https://doi.org/10.18632/oncotarget.9488.

Přehled o publikaci